Tissium, a French startup developing a novel technology to reconstruct damaged tissue and restore it to its natural state, has raised €30 million in equity alongside up to €30 million in debt financing.
The equity tranche brings meaningful capital to the company, while the debt facility provides additional flexibility. The round size reflects strong investor appetite for regenerative medicine solutions that address surgical reconstruction needs.
Tissium operates in the tissue engineering and regenerative medicine space, a market that has seen growing interest as clinical demand for minimally invasive repair options rises. The company's technology aims to set it apart from traditional grafts and synthetic implants by creating a scaffold that mimics natural tissue properties.
This capital injection signals continued momentum in European medtech startups focused on hard-tech biological solutions. It also highlights the trend toward blending equity and debt instruments to stretch runway without excessive dilution, a structure becoming more common in capital-intensive biotech ventures.
No specific investors or valuation details were disclosed in the source report. The company did not provide commentary on how it plans to deploy the funds beyond advancing its platform toward clinical or commercial milestones.